Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis

Malik, Adnan; Nadeem, Mahum; Amjad, Waseem; Malik, Muhammad Imran; Javaid, Sadia; Farooq, Umer; Naseem, Khadija; Khan, Ahmad

doi:10.5114/pg.2022.113573

Cited by 2 publications

(2 citation statements)

References 32 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] FLD can be divided into alcoholic fatty liver and nonalcoholic fatty liver, with 90% of cases attributed to metabolic factors, namely nonalcoholic fatty liver. [17] According to relevant studies, the risk of fatty liver disease is much higher in people who have a long-term high salt, high oil, and high sugar diet than in those who have a normal diet. [14] At the same time, relevant research data show that the liver function of patients with basic metabolic diseases is significantly lower than that of normal people, and the incidence rate of fatty liver is much higher than that of normal people.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the detection rate and related factors of fatty liver disease in physical examination of healthy population in Chengdu district

Han,

Guo,

Gong

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: In the present study, we analyzed the detection rate and related influencing factors of fatty liver in the health examination population in Chengdu area. Methods: The case-control study was performed to compare the gender, age (years), body mass index (BMI), smoking, drinking, abnormal lipid metabolism, hypertension, hyperglycemia, hyperuricemia Is there any statistically significant difference in the detection rate of diseases such as metabolic syndrome, and logistic regression analysis is conducted to analyze the comprehensive impact of each influencing factor on the prevention of fatty liver disease. Results: Among 14,426 survey subjects, a total of 6717 patients with fatty liver were detected, with a detection rate of 47.22%. There are significant differences in the incidence of fatty liver disease among different gender groups, with the incidence rate in males being significantly higher than that in females (P < .05); The incidence of fatty liver in elderly subjects was significantly higher than that in middle-aged and young subjects (P < .05); The prevalence rate of individuals with a BMI > 24 was significantly higher than that of individuals with a BMI < 24 (P < .05). The prevalence of fatty liver in the population with abnormal lipid metabolism, hypertension, hyperglycemia, hyperuricemia, metabolic syndrome and other diseases was significantly higher (P < .05); After stratified analysis by gender and age, the incidence of fatty liver in males was significantly higher than that in females in the 3 age groups < 60 years old (P < .05); In the age group ≥ 60 years old, the difference in the incidence of fatty liver disease between males and females was significantly reduced, and the difference was not statistically significant (P > .05). Conclusion: The health screening of patients with fatty liver should be carried out regularly, and attention should be paid to the intervention and prevention of overweight people and people with basal metabolism diseases such as hyperglycemia and hypertension, so as to reduce the incidence of fatty liver.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the detection rate and related factors of fatty liver disease in physical examination of healthy population in Chengdu district

Han,

Guo,

Gong

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…A systematic review and meta-analysis exploring the effects of aramchol vs. placebo in patients with steatotic liver and including 3 clinical trials, documented any effect of this drug on ALT, AP, glycated hemoglobin, total cholesterol, triglycerides, insulin resistance, and insulin levels [ 323 ]. However, in the ARREST phase, 2b double-blind trial, aramchol 600 mg/per day for 52 weeks in patients with overweight or obesity and prediabetes was safe, reduced liver fat by −16.7% in hepatic lipid accumulation compared to only a −5% in the placebo group.…”

Section: Therapeutic Management Of Masldmentioning

confidence: 99%

Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

Portincasa,

Khalil,

Mahdi

et al. 2024

IJMS

View full text Add to dashboard Cite

The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from “nonalcoholic fatty liver disease” (NAFLD) to “metabolic dysfunction-associated fatty liver disease” (MAFLD) and, finally, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH.

show abstract

Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis

Cited by 2 publications

References 32 publications

Analysis of the detection rate and related factors of fatty liver disease in physical examination of healthy population in Chengdu district

Analysis of the detection rate and related factors of fatty liver disease in physical examination of healthy population in Chengdu district

Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options

Contact Info

Product

Resources

About